报价延迟最少15分钟:2025/07/27 06:53 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.80/-3.36
|
|
企业价值
559.09M
|
| 资产负债 |
|
每股账面净值
6.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
41.24M
|
|
每股收益
0.18
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/27 06:53 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |
